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Background
While b-adrenergic blockade is a cornerstone of heart
failure therapy, its therapeutic role in chronic mitral
regurgitation remains questionable. Animal studies and a
small clinical trial have demonstrated cardiac functional
improvement with b1-adrenoceptor blocker metoprolol
in chronic mitral regurgitation [1,2]. How b1AR-blockade
halts functional decline of the volume-overloaded,
eccentric hypertrophied heart is not well understood;
anti-oxidant effects of b-blockade (bB) may play a role.
We recently demonstrated that volume-overload cardiac
stress induces re-localization and microdomain-specific
oxidation of the nitric oxide receptor soluble guanylyl
cyclase (sGC) in the failing heart [3,4]. Given that nitric
oxide-cyclic guanosine monophosphate (NO-cGMP)
modulates cardiac contractility and protects against car-
diac hypertrophy, we hypothesized that b1AR-blockade
prevents oxidation of sGC and promotes myocardial
NO-cGMP signaling in a microdomain-specific fashion.
Materials and methods
Volume-overload (VO) was established by chordal rupture-
induced mitral regurgitation (MR) in mongrel dogs. Some
dogs were treated with metoprolol succinate (100mg orally
once daily; MR+ bB). Expression, localization, cyclase activ-
ity, and redox state of myocardial sGC were assessed in
Control, MR, and MR+bB dogs.
Results
sGCa1 and -b1 subunits were detected within and out-
side of caveolae-enriched lipid rafts (Cav3+LR). In MR,
total sGCa1 expression fell to nearly 50% of Control
and re-localized away from Cav3+LR to non-lipid raft
microdomains (NLR). While overall sGCb1 expression
was also less in MR+bB, caveolae-localization of sGCb1
was preserved. Overall NO-responsiveness of sGC
remained intact in MR hearts, irrespective of bB ther-
apy. However, a potentiated response to heme/NO-inde-
pendent sGC activator BAY 60-2770 suggested that a
subset of sGC was heme-oxidized in MR but not in
Control or MR+bB. Moreover, differential responses to
BAY 60-2770 and NO were noted in Cav3+LR and NLR
microdomains. In Control hearts, responses to BAY 60-
2770 and NO were similar within respective microdo-
mains, suggesting a predominantly reduced form of sGC
in both Cav3+LR and NLR of Controls. In contrast, BAY
60-2770 response of NLR-localized sGC was potentiated
in MR but not in MR+bB hearts, suggesting that bB
therapy prevented oxidation of NLR-localized sGC.
Moreover, BAY 60-2770 responses of Cav3+LR-localized
sGC were not potentiated in any hearts, suggesting an
anti-oxidation protection associated with caveolae-locali-
zation. These changes in caveolae-localization and redox
state of sGC were also reflected by microdomain distri-
bution of VASP phosphorylation.
Conclusion
b1AR blocker mediated cardioprotection in the volume-
overloaded heart is associated with enhanced microdo-
main specific myocardial NO-cGMP signaling, both
within and outside of caveolae. Such prevention of
volume overload-induced spatial and redox dysregula-
tion of myocardial sGC suggests novel strategies to
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